[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"openProblems","before":"[\"TP53-mutant AML remains lethal.\", \"Older patients.\"]","after":"[\"TP53-mutant AML: no drug class has yet improved survival, so it is the priority for new mechanisms.\", \"Older patients.\"]"}]},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"An aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived.\"","after":"\"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived.\""}]},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Fit\", approach: \"7+3 ± targeted agent; consolidation; allogeneic transplant by risk.\", refs: [\"gemtuzumab-ozogamicin\", \"cytotoxic-chemotherapy\"] },\n      { setting: \"Unfit\", approach: \"Azacitidine ...","after":"[\n      { setting: \"Fit\", approach: \"7+3 ± targeted agent; consolidation; allogeneic transplant by risk.\", refs: [\"gemtuzumab-ozogamicin\", \"cytotoxic-chemotherapy\"], guideline: { version: \"NCCN Guidelines: Acute Myelo..."}]}]